Update, November 6, 2026
UHS rose 11.0% over the past five sessions, closing at $195.50 on November 6, even as the S&P 500 fell 2.7% and XLV was flat (-0.04%). The stock was lifted by a broad post-election rally in healthcare after the Democratic sweep, though it pulled back 1.6% from its November 5 peak of $198.59. A Morningstar article noted healthcare stocks led gains on November 4, but a Wall Street Journal piece cautioned that hopes for reversing Medicaid cuts may be overblown.
The picture holds. The stock remains above its 40-week average and the daily trend is aligned with the weekly uptrend. The key level to watch is the swing zone at $190.53, which now serves as support; a daily close above $197.46 on above-average volume would signal an upside breakout, with a target of $244.18 (the 52-week high) and a stop at $188.43. The first crack below $190.53 would be a warning, but the trend would only end on a weekly close below $185.22. What would change the picture is a weekly close below that level.
Conviction has risen to high (3 of 4 points) as the stock leads the S&P 500 by 13.9% and XLV by 2.6% over 50 days. The next earnings are already past (October 27), and the company reiterated 2026 guidance toward the low end while flagging a $175M–$200M Medicaid headwind for 2027. The stock trades 1.5% above the analysts' mean target of $192.65, with a consensus buy rating.
Universal Health Services (UHS) trades at $180.04 on November 3, 2026, a week after a third-quarter report that beat estimates but pointed to the low end of 2026 guidance and a 2027 Medicaid headwind. The stock sits 4.3% below its October 22 peak yet above its 50-day and 200-day averages, and the weekly uptrend is intact. The balance of evidence leans positive for the next two to six weeks, with medium conviction.
Why it matters
On October 27, 2026, UHS reported adjusted earnings of $5.22 a share against a $5.20 consensus, and revenue of $4.73 billion, up 5.3% and ahead of the $4.71 billion estimate. Shares still fell 3% in after-hours trading, as a $26 million charge to raise reserves for a tentative legal settlement overshadowed the beat. Underneath, adjusted EBITDA slipped to $624.6 million from $670.6 million a year earlier. Management reiterated its 2026 ranges but said results are tracking toward the low end because de novo hospitals are ramping more slowly than expected, and it flagged a 2027 Medicaid supplemental headwind of $175 million to $200 million.
That explains why a beat was not rewarded. The market looked past the headline numbers to the quality of earnings: lower profit, a guidance range that is really its bottom half, and a revenue hole next year. The stock's peak close of $188.13 came on October 22, before the report, and it is now 4.3% lower. Today's 0.34% dip came on volume about half its 20-day average, so there is no sign of urgency in either direction. The sources give only the after-hours reaction, not a day-by-day path, so how much of the decline was the earnings and how much was drift cannot be separated.
The last five days are not a story about UHS alone. The stock rose 1.6% while the S&P 500 (SPY) fell 2.1% and the healthcare sector ETF (XLV) rose 2.8%. A rising sector carried the stock, and it still trailed the sector by 1.2 points. The pattern is the same over 50 days: UHS leads the S&P 500 by 3.2% but lags XLV by 5.0%. Year to date the stock is down 17.4% while SPY is up 10.5% and XLV is up 19.0%. The earnings news accounts for the drop from the peak, but not the five-day gain in a falling market. That looks like sector strength, with XLV up 10.9% over the past month.
The real argument is about Medicaid policy. The Wall Street Journal describes investors buying hospital operators on the expectation that a Democratic House could reverse Trump-era Medicaid cuts, and cautions that such rollbacks are hard to deliver, citing past cases where an opposition party failed to follow through. The company's own $175 million to $200 million 2027 headwind shows how much rides on that bet. The supportive case is the analyst community: 17 analysts rate the stock a buy, with a mean price target of $192.41 in a range of $156 to $250. At $180.04 the shares are 6.4% below that mean, in the lower half of the spread.
What the evidence says
The long-term thesis is intact but unfinished. Price is above both its 10-week and 40-week averages, and the 50-day average ($177.42) sits just above the 200-day ($176.77). Yet the stock is 26.3% below its 52-week high of $244.18 and only 27.5% above the low of $141.17. This is a recovery inside a longer-term uptrend, not a return to the highs, and the Q3 guidance language gives that recovery less fundamental support than it had a month ago.
For the next two to six weeks the balance of evidence leans positive, with medium conviction: two of four checks are in its favor. The daily trend runs with the weekly uptrend, and UHS has led the S&P 500 over 50 days. The stock is also holding above its 50-day average despite an earnings reaction that could have broken it. The strongest case against that reading is the relative picture. UHS lags its own sector by 5.0% over 50 days, which is against the trend, and the stock was outpaced by XLV even in a week when it rose. The 14-day RSI of 43.35 is soft, volume is 49.2% below average, and the earnings language leans cautious. None of that has pushed price below the averages that define the trend, so it does not tip the balance. It is why conviction is medium rather than high.
Levels that matter
The structure holds above $177.42, the 50-day average, with the 200-day average at $176.77 and the round $175 just beneath it. A daily close under $177.42 would be the first crack. The weekly trend would end on a weekly close below $165.66, the swing zone that marks the last meaningful support before $150.
Upside, the first resistance is $180.68, almost exactly where the stock trades. A daily close above it on volume above the 20-day average would be the first sign that buyers are back; volume is currently far below that bar. From $180.68 the first target is $185.22, which gives 0.9 to 1 against a stop at $175.72 (the 50-day average minus a quarter of the 14-day ATR). The second is $190.53, at 2.0 to 1. The math does not reach 3 to 1 at either level. Only a target as far as the next resistance, $196.70, would carry it past that mark.
What would change the picture
A weekly close below $165.66 would end the weekly uptrend and turn the evidence negative. The non-price fact that would most likely cause it is management moving 2026 results below its reiterated ranges, rather than toward the low end of them. That would turn the current worry about earnings quality into a cut to the numbers themselves.
What to watch
- Next earnings: the data lists October 27, 2026 as the latest report and gives no later date. The number that matters is adjusted EBITDA against $624.6 million this quarter and $670.6 million a year ago.
- November 10, 2026: UHS presents at the UBS Global Healthcare Conference at 9:30 a.m. Eastern. It is the first management commentary since the report.
- Sector: Medicaid policy and the House outcome behind the WSJ debate, plus XLV's momentum, can move the stock before any company news.
- Valuation: $180.04 against a $192.41 mean price target, with analyst targets running from $156 to $250.